Objective of this research was to assess the variation in cost among different brands of anticancer drugs available in Indian pharmaceutical market. The price of different brands of the anticancer drugs available in the Indian pharmaceutical market was assessed. The drug cost was analyzed according to the availability of parenteral and oral drug formulations dosage form. The difference in the maximum and the minimum cost variation of the anticancer drugs manufactured by different pharmaceutical companies was determined; the percentage variation in price was calculated. Percentage variation in cost was analyzed for 41 different formulations of 20 anticancer drugs. Highest cost variability is seen with Estramustine 140 mg capsule (6726.3%) and the lowest with Goserelin 3.6mg injection (13.79%). 12 formulations showed more than 500% cost variation, largest with Estramustine 140mg capsule (6726.3%) followed by Decitabine 50mg injection (1706%), Hydroxyurea 500mg capsule (1700%), Bicalutamide 50mg tablet (1467.9%), Chlorambucil 2 mg tablet (1395%), Bosutinib 100 mg tablet (1,108.7%), Cabazitaxel 60/1.5 ml injection (805.6%), Cabazitaxel 60mg injection (796.5%), Melphalan 2mg tablet (769.99%), Dactinomycin 0.5mg injection (671.69%), Melphalan 5mg tablet (528.81%) and Fludarabine 10mg tablet (514.2%).
Loading....